A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...

COMMENT: The monthly cost of a private prescription exceeding £300 from next month is worrying news for the half a million ...

Mounjaro and other GLP-1 drugs may lower cancer risk in obese patients, according to a new study. Read more here.

What started as a medical solution to diabetes has exploded into a worldwide weight-loss trend, with demand skyrocketing as ...

Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...

Dr Shazia Malik - a consultant obstetrician and gynaecologist for The Portland Hospital - discussed the pros and cons of ...

Lilly's obesity pill orforglipron disappointed with lower weight loss, but its broad late-stage pipeline keeps growth hopes ...

A NEW drug developed to combat diabetes and obesity melts fat at double the rate of other GLP-1 drugs, scientists say. The ...

The logistics park, which has been developed under the company's Invest in Kerala initiative, seeks to transform the state of ...

Novo Nordisk announced it is cutting ties with telehealth giant Hims & Hers Health, pulling its blockbuster drug Wegovy from ...

According to Bloomberg, the reduction in bonuses will apply to employees who are eligible for short-term incentives in ...

After years of struggling with postpartum weight gain despite strict training and healthy eating, the 23-time Grand Slam ...